top of page

Lessons from insulin - curbing the price of novel diabetes and obesity medications

For years, Dr Kasia Lipska, associate professor of medicine (endocrinology) at Yale School of Medicine (YSM), has been advocating for affordable pricing of insulin, an essential and lifesaving drug for many diabetics. Now, she is turning her attention to a similar trend of soaring prices among new diabetes and obesity medications.

The implications of exorbitant prices for these novel therapies are alarming, according to Lipska, who first became aware of the drug pricing issue in 2016 when one of her patients couldn't afford to increase the dose of insulin she was taking. In subsequent research, Lipska discovered that 1.1 million Americans (14 percent of those who filled insulin prescriptions) reached catastrophic spending, defined as spending more than 40 percent of post-subsistence income on insulin alone. The same insulin and other medications for diabetes and obesity are frequently priced 10 times higher in the US than in peer countries, said noted.


Using findings from previous research on insulin pricing, Lipska, Dr Reshma Ramachandran (assistant professor of medicine (general medicine) at YSM) and Dr Kathryn Nagel (former YSM Department of Internal Medicine resident), looked at the issues underlying drug affordability.

In their research and analysis, they gathered evidence about the changes needed to achieve fair pricing of new diabetes and obesity drugs, creating a blueprint that policymakers can use for potential action.


"Writing the article helped us map out the different pieces that go into the drug pricing process in the US," Lipska explained. "We learned more about the complex chain of events that leads from drug development and patent law to how much patients pay when the medicine gets to them."


"As with insulin, our patients are facing parallel challenges in accessing other new non-insulin diabetes and anti-obesity medications," Ramachandran said. "Our paper highlights where along the drug development and delivery value chain there is more work yet to be done by policymakers to enable more equitable and affordable access to these medications."


Ramachandran noted a key lesson learned from efforts to improve access to insulin is that there is no single silver bullet. "Our paper shows that a range of upstream and downstream policies are necessary," she said. But there are challenges to policy reform, the researchers observed.

"While the recent Inflation Reduction Act includes several policies to lower prescription drug prices, including for those used in diabetes treatment, the legislation also has serious limitations in providing relief for patients, particularly for novel, transformative treatments," Ramachandran said.


"Many patient advocacy groups, educational events, and even professional societies that clinicians are a part of are in some way influenced or supported by the pharmaceutical industry," said Lipska, acknowledging the power of US corporations as another obstacle to drug affordability.

Still, the issue is gaining traction, Lipska says. She notes a growing awareness of the need to address the drug pricing crisis through state and federal intervention and of the role clinicians can play in advocating on behalf of their patients.


"There are a lot of policies targeting drug affordability that have recently been proposed or enacted into law," she said. "Clinicians can give feedback about how certain solutions are playing out in practice and bring an important perspective to this conversation."


The findings were reported in the paper, 'Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications, published in Diabetes Care.

 

Graphical Abstract. Credit: Diabetes Care (2024). DOI: 10.2337/dci23-0042

Comentarios


bottom of page